UpToDate’s Post

Wrapping up clinical trials! Empros is pleased to announce that we have had the Last Subject Last Visit in our clinical trial COBEX, a Phase 1, active-controlled, randomized crossover PK/PD trial. We are very proud to demonstrate that our EMP16 drug development project delivers on time and brings us one step closer to addressing the medical needs of patients with obesity. In parallel, we have the ongoing Phase 2b SESAM trial, where we expect to have the Last Patient Last Visit before the end of the year #lifescience #drugdevelopment #clinicaltrials#obesity #obesitytreatment

ALS, or Lou Gehrig’s Disease, is a disease that causes progressive degeneration of nerve cells in the spinal cord and brain. It affects 30,000 people in the US every year and treatment for it focuses primarily on reducing discomfort and slowing disease progression. US-based company Spinogenix, Inc. is developing a novel drug therapy for ALS that focuses on restoring synapses for patients affected with this disease. The treatment developed is a once-a-day pill that targets synapse loss, which is central to ALS. The company has just received FDA clearance for Investigational New Drug Application for its clinical trials in Australia. Studies so far in healthy volunteers have shown excellent tolerability and plasma levels aligned with efficacy in animal models. Read more about this drug here: https://lnkd.in/g3XiHc6d . . . #research #SimplerScience #als #healthcare #treatment #futureofhealthcare

Synergy Healthcare is thrilled to share groundbreaking developments in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The Food and Drug Administration (FDA) is on the verge of approving the first-ever medicine specifically designed to combat this serious liver disease. Developed by Madrigal Pharmaceuticals, the pill, known as resmetirom, targets a protein in the liver, effectively reducing liver fat, inflammation, and scarring associated with MASH. If approved, resmetirom will mark a significant milestone in healthcare, offering hope to patients with advanced stages of MASH where current treatments have shown limited effectiveness. At Synergy Healthcare, we pride ourselves on being at the forefront of clinical research, especially in metabolic and neurological diseases. The potential approval of resmetirom represents a significant step forward in addressing the unmet medical needs of patients suffering from MASH. The addressable market for drugs to treat advanced MASH is substantial, with an estimated 315,000 individuals in need of effective treatment. Resmetirom's innovative approach and promising clinical trial results position it as a potential game-changer in the field of liver disease treatment. We commend the dedication and perseverance of researchers and scientists, including those at Madrigal Pharmaceuticals, for their tireless efforts in bringing new therapeutic options to patients in need. Stay tuned for more updates as we eagerly await the FDA's decision on resmetirom, and let's continue our collective efforts to advance healthcare and improve patient outcomes! 💊💪 #SynergyHealthcare #ClinicalResearch #MASHTreatment #Resmetirom #HealthcareInnovation #LiverDiseaseTreatment #FDAApproval #MedicalBreakthroughs 🔗 https://lnkd.in/ekjzn4uy

MASH is the newest area of intervention in metabolic health. Earlier this year, Rezdiffra (resmetirom) was launched, but at $48K a year and with very minimal results, there is still a lot to be desired. #GLP1 are also under the microscope in this space. Lilly released information on their trial this past week- https://lnkd.in/gT88XYuD And more novel therapies to come: https://lnkd.in/gKKQ84h7 https://lnkd.in/gkCZAfkU Lots to watch in this space over the next few years! #Pharmacists #Pharmacybenefits #liver #newdrugapproval #GLP1

▶ New Lp(a) clinical trial Amgen Inc. is sponsoring a global, phase 3, double-blind cardiovascular outcomes study titled the OCEAN(a)-Outcomes Trial (The OCEAN(a) (Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction – Outcomes Trial) to compare the effect of treatment with with investigational drug olpasiran to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein(a).

🚀 Exciting News Alert! 🚀 Beckley Psytech reports positive initial findings from their Phase IIa clinical study (NCT05660642) of BPL-003 (5-MeO-DMT) for Treatment Resistant Depression (TRD). BPL-003 is benzoate salt formulation of 5-MeO-DMT (Mebufotenin), administered intranasally. In this open-label study, a single 10mg dose of BPL-003 was well-tolerated and demonstrated rapid, durable efficacy in patients with TRD. Key highlights include: ·      Rapid antidepressant response observed in 55% of patients the day after dosing. ·      55% of patients in remission from depression at day 29 and 45% at day 85 post-dosing. “Acute effects were resolved and patients were deemed dischargeable within an average time of less than 2 hours. This signals the potential for a shorter treatment duration and reduced resource burden for healthcare systems compared to other psychedelic treatments currently in development.” #psychedelics #clinicaltrials #mentalhealth #treatmentresistentdepression

🔬 Exciting Updates in Alzheimer's Research! 🔬 In a surprise move, the FDA has delayed its decision on Eli Lilly’s Alzheimer’s drug, donanemab, and plans to convene an advisory committee for further review. At Synergy Healthcare, we're closely following this development as it underscores the importance of rigorous evaluation in advancing treatments for neurodegenerative diseases. Lilly's press release highlights the FDA's additional inquiries into safety, clinical trial design, and patient stratification, reflecting the thoroughness of the regulatory process. While this delay may raise questions, it demonstrates the FDA's commitment to ensuring the safety and efficacy of new treatments. Advisory committee meetings are integral to evaluating the relative benefits and risks of novel therapies. Despite the delay, Lilly remains optimistic, emphasizing that this doesn’t alter their financial outlook for 2024. This development underscores the complexity of Alzheimer's research and the need for tailored approaches in clinical trials. We remain committed to being a premier site for metabolic and neurological disease trials, contributing to groundbreaking advancements in healthcare. #AlzheimersResearch #ClinicalTrials #NeurologicalHealth #FDAApproval #SynergyHealthcare #MedicalResearch #Innovation #PatientCare #HealthcareAdvancements 🔗 https://lnkd.in/ejay6mMX

Living with Systemic Lupus (SLE)? You're not alone! Learn how to take part in the TOPAZ clinical research study evaluating an investigational drug for patients with SLE. Learn more here https://bit.ly/42YjbOp

Living with Systemic Lupus (SLE)? You're not alone! Learn how to take part in the TOPAZ clinical research study evaluating an investigational drug for patients with SLE. Learn more here https://bit.ly/42YjbOp

Why suffer when relief is within reach? Our devices offer relief from chronic pain and inflammatory diseases like never before. Learn why Gladiator Therapeutics is leading the way in medical breakthroughs. https://ow.ly/BzUX50QBf4X #GladiatorTherapeutics #ChronicPain #InflammatoryDisease #MedicalBreakthrough #MedicallyBacked #ClinicallyReviewed